Statistical Sampling: an Underestimated Element of Process Validation?
Recommendation
28-30 April 2026
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In a recent FDA Warning Letter, the FDA criticized inadequate process validation for a semi-solid dosage form. What exactly did the FDA find inadequate?
The validation studies were criticized for not reflecting inter- and intra-batch variability. In particular, there was criticism that the sampling was random. The viscosity sampling scheme does not lead to statistical confidence in process performance.
In a second Process Performance Qualification (PPQ) study, the influence of a critical excipient on viscosity was to be shown. Again, the FDA criticized that no inter-batch variability was demonstrated. This is not surprising, since only one run was performed.
As measures, the FDA requires:
- a validation programme, starting with product development, the validation itself and the control/monitoring of the processes with regard to intra- and inter-batch variability
- an equipment and premises qualification programme
- a programme for Process Performance Qualification and Continued Process Verification measures.
You can find the entire Warning Letter on the FDA website.
Related GMP News
22.04.2026Sampling: A Crucial Factor in Process Validation
22.04.2026Cleaning and Maintenance in the Focus of the FDA
15.04.2026Cleaning Validation Technical Guide - What Does China Expect in Terms of Cleaning Validation?
11.03.2026Risk Assessment as the Basis for Process Validation
25.02.2026Rationale for Limit Selection in Process Validation
25.02.2026The GMP Relevance of Equipment Maintenance from FDA's Perspective